Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
GENEVA, Switzerland, January 16 /PRNewswire-FirstCall/ — Merck Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety [...]
What Causes Multiple Sclerosis?
What causes multiple sclerosis? I hate to say it but this is going to be a very short post because the answer isn’t a very good one.
So, what causes ms? It’s not actually known, yet, What causes multiple sclerosis. Much research has been done, and is continuing to be done, in an [...]